Skip to main content

Polycystic kidney disease (ADPKD)

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.
N Engl J Med. 2017 Nov 4

Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease

Steven Soroka, Ahsan Alam, Micheli Bevilacqua, Louis-Philippe Girard, Paul Komenda, Rolf Loertscher, Philip McFarlane, Sanjaya Pandeya, Paul Tam, Daniel G. Bichet
Can J Kidney Health Dis. 2017; 4: 2054358117695784.

Tolvaptan in patients with autosomal dominant polycystic kidney disease

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators
N Engl J Med. 2012 Dec 20;367(25):2407-18

Volume progression in polycystic kidney disease (CRISP)

Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP; CRISP Investigators
N Engl J Med. 2006 May 18;354(20):2122-30
ukidneyisup